Immunosuppressants - Bhutan

Bhutan

The Immunosuppressants market in Bhutan is expected to witness a significant increase in revenue, reaching US$217.70k by 2024.
This projection indicates a positive growth trend in the market.
Furthermore, it is anticipated that the market will continue to expand at an annual growth rate of 15.07% (CAGR 2024-2029), resulting in a market volume of US$439.30k by 2029.
When compared globally, it is noteworthy that United States is projected to generate the highest revenue in the Immunosuppressants market, amounting to US$35,470.00m in 2024.
This demonstrates the significant market presence and potential of the United States in the pharmaceutical industry.
Bhutan's immunosuppressants market is witnessing a growing demand due to the increasing prevalence of autoimmune disorders in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Bhutan has been steadily growing over the years, driven by increasing demand for treatments for autoimmune diseases, organ transplants, and other conditions that require immunosuppressive therapy.

Customer preferences: Patients in Bhutan generally prefer generic immunosuppressants due to their lower cost compared to branded drugs. This preference is driven by the high cost of healthcare in the country and the limited availability of health insurance coverage.

Trends in the market: The immunosuppressants market in Bhutan is expected to continue its steady growth in the coming years, driven by increasing prevalence of autoimmune diseases and organ transplant surgeries. The market is also expected to benefit from the growing availability of generic immunosuppressants, which are expected to become increasingly popular due to their lower cost.

Local special circumstances: Bhutan is a small country with a population of just over 750,000 people, which limits the size of the immunosuppressants market. Additionally, the country's healthcare system is still developing, which has led to limited access to healthcare services and a shortage of medical professionals. These factors have contributed to the relatively low demand for immunosuppressants in the country.

Underlying macroeconomic factors: Bhutan's economy is heavily reliant on agriculture and hydroelectric power generation, which limits the country's ability to invest in healthcare infrastructure and research and development. Additionally, the country's small population and geographical isolation make it challenging for pharmaceutical companies to enter the market and distribute their products effectively. These factors have contributed to the relatively slow growth of the immunosuppressants market in Bhutan.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.